Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL : a 36-month analysis of a phase I and II study
-
- USUKI Kensuke
- Division of Hematology, NTT Kanto Medical Center
-
- TOJO Arinobu
- The Institute of Medical Science, The University of Tokyo
-
- MAEDA Yasuhiro
- Kinki University School of Medicine
-
- KOBAYASHI Yukio
- National Cancer Center Hospital
-
- MATSUDA Akira
- International Medical Center, Saitama Medical University
-
- OHYASHIKI Kazuma
- Tokyo Medical University Hospital
-
- NAKASEKO Chiaki
- Chiba University Hospital
-
- KAWAGUCHI Tatsuya
- Kumamoto University Hospital
-
- TANAKA Hideo
- Hiroshima University Hospital
-
- MIYAMURA Koichi
- Japanese Red Cross Nagoya First Hospital
-
- MIYAZAKI Yasushi
- Nagasaki University Hospital
-
- OKAMOTO Shinichiro
- Keio University Hospital
-
- ORITANI Kenji
- Osaka University Hospital
-
- OKADA Masaya
- Hyogo College of Medicine
-
- USUI Noriko
- The Jikei University Daisan Hospital
-
- NAGAI Tadashi
- Jichi Medical University Hospital
-
- AMAGASAKI Taro
- Novartis Pharma Japan
-
- WANAJO Aira
- Novartis Pharma Japan
-
- NAOE Tomoki
- Nagoya University Hospital
この論文をさがす
収録刊行物
-
- International journal of hematology
-
International journal of hematology 95 (4), 409-419, 2012-04-01
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1571980075691774848
-
- NII論文ID
- 10030632609
-
- NII書誌ID
- AA10797094
-
- ISSN
- 09255710
-
- 本文言語コード
- en
-
- データソース種別
-
- CiNii Articles
